New Republic Capital’s AstraZeneca AZN Stock Holding History

New Republic Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$537K	Sell	2,723 -1,683	-38%	-$325K	0.18%	105
2025 Q4	$810K	Buy	4,406 +2,644	+150%	+$464K	0.22%	89
2025 Q3	$270K	Buy	1,762 +298	+20%	+$45.1K	0.08%	148
2025 Q2	$205K	Sell	1,464 -90	-6%	-$12.6K	0.07%	174
2025 Q1	$228K	Sell	1,554 -172	-10%	-$24.9K	0.1%	154
2024 Q4	$226K	Buy	+1,726	New	+$242K	0.15%	149
2024 Q3	–	Sell	-1,394	Closed	-$217K	–	241
2024 Q2	$217K	Buy	+1,394	New	+$210K	0.11%	162

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

New Republic Capital's AZN Position: Q1 2026 in Review

New Republic Capital reduced its AstraZeneca (AZN) stake by 38% in Q1 2026, selling an estimated $325K and leaving 2,723 shares worth $537K. The position accounts for 0.18% of the portfolio, ranked #105.

New Republic Capital first reported a position in AZN in Q2 2024 and has held it in 7 quarters since. The position peaked at $810K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

New Republic Capital held 2,723 shares of AstraZeneca worth $537K as of Q1 2026.
New Republic Capital sold 1,683 AstraZeneca shares in Q1 2026, an estimated $325K.
AstraZeneca made up 0.18% of New Republic Capital's portfolio in Q1 2026, its #105 holding.
New Republic Capital first reported a position in AstraZeneca in Q2 2024 and has held it in 7 quarters since.
New Republic Capital's AstraZeneca position peaked at $810K in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on New Republic Capital's 13F filing for Q1 2026, filed 1 May 2026.